Drug Approval | March 28, 2026
Alembic receives USFDA final approval for Paroxetine Extended-Release Tablets
Paroxetine extended-release tablets are indicated for the treatment of major depressive disorder
Paroxetine extended-release tablets are indicated for the treatment of major depressive disorder
Kedar Upadhye has also been appointed as Chief Financial Officer of Biocon Limited
The move leverages Novartis’ deep expertise in IgE biology and long-standing presence in allergic disease treatments
Otsuka will pay $700 million to Transcend shareholders at closing, with an additional $525 million in contingent payments tied to future sales milestones
The programme aims to provide critical healthcare services to approximately 4 lakh people in remote and resource-scarce communities
STADA will market and distribute two EMA approved biosimilars developed by CuraTeQ in select European Union territories
The Trust’s shift from single-use compostable cups to a reusable system was driven by the need to reduce environmental impact and control long-term costs
Since launching, the hospital has performed over 40 intestinal transplants, including 21 in 2025 alone
They stressed that while the drug is clinically proven to support weight and blood sugar control, it must be prescribed only after careful patient evaluation and used under strict medical supervision.
Doctors at the hospital highlighted that robotic-assisted surgery enhances precision through superior 3D visualisation and improved instrument flexibility
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
